Danaparoid

Generic name
Danaparoid
Brand name
ATC Code
B01AB09
Compare …

Danaparoid

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

There is no specific data for children.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Prophylaxis of deep venous thrombosis in heparin-induced thrombocytopenia
  • Subcutaneous
    • < 2 years
      • 8 - 144 AntiXa/kg/day in 2 - 3 doses.

      • Target plasma anti-Xa activity level: 0.1-0.4 IU/ml

    • 2 years up to 7 years

      • No data known for this age category (source: SmPC)

    • 7 years up to 18 years
      • 20 - 25 AntiXa/kg/day in 2 - 3 doses. Max: 1.500 AntiXa/day.

      • Target plasma anti-Xa activity level: 0.1-0.4 IU/ml
Treatment of deep venous trombosis in heparin-induced thrombocytopenia (HIT)
  • Intravenous
    • 7 months up to 18 years
      • Initial dose: 30 AntiXa/kg/dose, once only.
      • Maintenance dose: 1.2 - 2 AntiXa/kg/hour, continuous infusion.
      • Duration of treatment:

        Daily check of the anti-Xa level (target value: 0.4-0.8 IU/ml)

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Dose adjustment not needed
GFR 30-50 ml/min/1.73 m2
Monitor anti-Xa levels
GFR 10-30 ml/min/1.73 m2
Monitor anti-Xa levels
GFR < 10 ml/min/1.73 m2
A general recommendation is not provided
Clinical consequences

Danaparoid is excreted primarily with the urine; accumulation of danaparoid can be expected to occur with decreased renal function. This increases the risk of bleeding.

Clinical implications:
The main complication of treatment with heparins is the occurrence of bleeding.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children of the same age and weight can react differently to the given dose. That is why the dose should be determined based on the plasma anti-Xa levels and the balance between the intended effectiveness and the risk of bleeding.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTITHROMBOTIC AGENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Vitamin K antagonists
B01AA07
B01AA04
Heparin group
B01AB04
B01AB05
B01AB01
B01AB06
B01AB10
Platelet aggregation inhibitors excl. heparin
B01AC06
B01AC04
B01AC09
Enzymes
B01AD02
B01AD01
B01AD04
Direct thrombin inhibitors
B01AE07
Direct factor Xa inhibitors
B01AF02
B01AF01

References

  1. Aspen Pharma Trading Limited, SPC Orgaran (RVG 15006) 31-10-2018, www.geneesmiddelinformatiebank.nl
  2. Chan VH, Novel paediatric anticoagulants: a review of the current literature., Blood Coagul Fibrinolysis., 2010, Mar;21(2), 144-51
  3. NKFK Workinggroup Acute Kidney Impairment, Extrapolation of KNMP risk analysis "Impaired renal function" for adults to children, 20 Dec 2021

Changes

Therapeutic Drug Monitoring


Overdose